Home
Questo sito è destinato ai professionisti sanitari.

Modulo 4 del Navigator sulla fibrosi polmonare: Il colloquio difficile

Condividi

Descrizione

Questa attività è sostenuta da una sovvenzione formativa indipendente concessa da BMS. Questo programma formativo online è stato ideato per gli operatori sanitari di tutto il mondo, ad eccezione del Regno Unito.

Unitevi all’esperto Fernando Martinez, MD, per una guida pratica su come integrare la pianificazione proattiva delle cure (ACP) nella gestione longitudinale delle ILD. Questa sessione esplora come alcuni fattori clinici oggettivi, quali il declino funzionale e lo stadio ILD-GAP, segnalino la necessità di avviare discussioni parallele sulle cure di supporto insieme al trattamento modificante la malattia.

Questo è il quarto modulo su quattro. I moduli uno, due e tre sono disponibili qui.

Punti salienti della sessione

  • Avviare tempestivamente le discussioni sulla pianificazione delle cure, utilizzando parametri clinici oggettivi come la stadiazione ILD-GAP e il declino funzionale, anziché attendere l’insorgere di crisi acute.
  • Attuare strategie di comunicazione empatiche e incentrate sul paziente che chiariscano le preferenze assistenziali, gli obiettivi terapeutici e i limiti di escalation senza ricorrere a gergo tecnico.
  • Integrare percorsi di cure di supporto e palliative parallelamente alle terapie antifibrotiche in corso per mantenere la qualità della vita del paziente.
  • Documentare le decisioni relative alla pianificazione anticipata delle cure direttamente all’interno di dashboard condivise per garantire una chiara visibilità multidisciplinare e la continuità delle cure.

Destinatari

Questa attività è rivolta a pneumologi, reumatologi, radiologi toracici, patologi, infermieri specializzati in pneumologia e assistenti medici che svolgono un ruolo centrale nella diagnosi e nella gestione della fibrosi polmonare idiopatica (IPF) e della fibrosi polmonare post-polmonite (PPF). È inoltre pensata per medici di base, terapisti respiratori, farmacisti e altri professionisti sanitari multidisciplinari coinvolti nella cura dei pazienti affetti da fibrosi polmonare.

Docenti

Il dott. Fernando Martinez è professore presso la Divisione di Medicina Polmonare e presidente ad interim del Dipartimento di Medicina presso la Chan Medical School dell’Università del Massachusetts a Worcester, Massachusetts. Titolare di un dottorato in medicina (MD) e di un master (MS), è un clinico e ricercatore di spicco con un impegno di lunga data nella medicina accademica, nella cura dei pazienti e nelle strategie multidisciplinari in medicina respiratoria.

Informativa

In conformità con le linee guida EBAC®, tutti i relatori e i moderatori che partecipano a questo programma hanno dichiarato o segnalato eventuali conflitti di interesse che potrebbero influenzare in modo distorto le loro presentazioni. Il Comitato Organizzatore/Direttore del corso ha la responsabilità di garantire che tutti i potenziali conflitti di interesse rilevanti per l’evento siano comunicati al pubblico prima dell’inizio delle attività di formazione continua.

Il dott. Fernando Martinez, docente di questa attività, ha dichiarato di aver intrattenuto rapporti finanziari negli ultimi 36 mesi con le seguenti aziende non ammissibili: consulente per Lung Therapeutics; consulente, advisor e relatore per Boehringer Ingelheim e Chiesi; membro del DSMB per Pliant; ricercatore per AstraZeneca, Bristol Myers Squibb, Chiesi, DevPro e Vicore.

Il personale di MedAll, così come i responsabili della pianificazione e i revisori, non hanno rapporti finanziari rilevanti da dichiarare con aziende non ammissibili.

Informazioni CME EBAC®:

Questa attività è stata pianificata e realizzata in conformità con i requisiti e le politiche di accreditamento dell’European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

MedAll è un fornitore accreditato dall’EBAC dal 2025. Il Consiglio europeo per l’accreditamento della formazione continua per i professionisti sanitari (EBAC) accredita i programmi di formazione continua (CE) per la comunità medica internazionale.

Questo programma è accreditato dal Consiglio europeo per l’accreditamento della formazione continua per i professionisti sanitari (EBAC®) per 15 minuti di tempo di formazione effettivo.

In conformità con le linee guida dell’EBAC, tutti i relatori/moderatori che partecipano a questo programma hanno dichiarato o segnalato potenziali conflitti di interesse che potrebbero causare una parzialità nelle presentazioni. Il Comitato Organizzatore/Direttore del corso ha la responsabilità di garantire che tutti i potenziali conflitti di interesse rilevanti per l’evento siano dichiarati al pubblico prima dell’inizio delle attività di formazione continua.

L’EBAC® ha stipulato un accordo di riconoscimento reciproco dell’equivalenza sostanziale rispettivamente con l’Accreditation Council for CME (ACCME) degli Stati Uniti e con il Royal College of Physicians and Surgeons of Canada.

Grazie a un accordo tra l’European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) e l’American Medical Association, i medici possono convertire i crediti ECM esterni EBAC® in crediti AMA PRA di Categoria 1. Le informazioni sulla procedura per convertire i crediti EBAC® in crediti AMA sono disponibili sul sito web dell’AMA. Altri professionisti sanitari possono ottenere dall’AMA un certificato di partecipazione a un’attività idonea alla conversione dei crediti in crediti AMA PRA di Categoria 1.

L’Accreditation Council for Continuing Medical Education (ACCME) e il Royal College of Physicians and Surgeons of Canada hanno stipulato un accordo di equivalenza sostanziale dei sistemi di accreditamento con l’EBAC.

L’EBAC® è membro dell’Accademia Internazionale per l’Accreditamento della Formazione Professionale Continua (IACPDA) e membro partner dell’Associazione Internazionale delle Autorità di Regolamentazione Medica (IAMRA).

Come ottenere i crediti ECM EBAC®:

Per ottenere i crediti ECM e ricevere il certificato, si prega di partecipare all’attività e di completare la valutazione finale. Dopo aver completato la valutazione, riceverete un link al vostro certificato.

Costi di partecipazione

La partecipazione a questo programma è gratuita.

Questa attività di formazione continua è attiva a partire dal 1° novembre 2026 e scadrà il 30 settembre 2027.

Tempo stimato per il completamento di questa attività: 15 minuti

Obiettivi formativi

Al termine di questa attività, i partecipanti saranno in grado di:

  • Integrare la stratificazione del rischio, l’imaging ad alta risoluzione e la valutazione multidisciplinare per differenziare e diagnosticare precocemente e con precisione la fibrosi polmonare idiopatica (IPF) e la fibrosi polmonare post-polmonite (PPF) rispetto ad altre malattie polmonari interstiziali (ILD).
  • Attuare strategie diagnostiche e gestionali multidisciplinari per migliorare il riconoscimento tempestivo, l’invio a specialisti e l’assistenza coordinata per i pazienti affetti da fibrosi polmonare (PF).
  • Applicare le conoscenze relative ai meccanismi d’azione e alle evidenze cliniche alle decisioni terapeutiche, compresa la selezione dei pazienti e la tempistica della terapia.

Community simili

Visualizza tutto

Eventi e video on-demand simili

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So here we are 18 months later, um, we're trying to impress upon you the value of having some type of a dashboard that would give you sort of hints during the management of the patient. This is now a new kind of flag, and it wasn't that one that's not necessarily related to any specific medication, because here you are sitting with Margaret, you've heard her little uh components there. Uh, and over the last 18 months, you know that she's had an elevated gap score, so she's at advanced risk for progression. And sure enough, the lung function parameters demonstrate that her forced vital capacity has been steadily going downhill. Her DLCO is pretty poopy, and most of Importantly, she's noticing it. She is now not able to do the same as she was doing before. She's can't go up a flight of stairs, uh, she can't go up a hill, uh, and so part of what we want you to understand within the concept of this sort of holistic multidisciplinary approach is to have a sense that this person is at risk and has had functional decline, but there's been no documentation of uh advanced care approaches. And so here we are, 18 months of monitoring her going downhill, and no one's addressed this conversation. So, the question here is the gap, and by this, I don't mean ILD gap, but I mean the gap in her care, isn't really her numbers, it's that we haven't done a good job in providing this care. And so this is part of what we want to try to impress upon you the importance of looking at something like, so this is your hypothetical, uh, dashboard, and what you're looking at is, OK, there's a little Warning on Margaret, uh, who's got, uh, rheumatoid arthritis and associated ILD. She's had an elevated gap stage, so sort of physiologically and clinically, we know she's at risk. In fact, we've documented that there's progression in her pulmonary functions, and she's symptomatically noticing it. And when we look at our, our concepts of advanced uh care planning, That there's just no clear documentation that we've addressed, uh, what she wants, uh, how she wants to be managed, goals of care, place of care, what she wants to do therapeutically and non-ph pharmaco therapeutically for sort of escalation preferences, and there's no evidence that there's been any advanced care planning in her record. Uh, and I think that, that's where we want. To adjust ourselves, our practice pattern, to avoid this gap in care, which is to address the progressive nature of this disorder. So here we come back to, um, to Margaret. Uh, we, we've got a clinician who's talking with her, uh, and, and I want you to sort of to, to look at the way this interaction takes place, uh, and think about it if this were you, uh, what was good. What was that good? What could have been done better? What tools could I have used to better support this, uh, discussion and, and see what, how you guys would, would, would manage this, uh, in, uh, in Margaret's case. Margaret, good to see you. So your numbers, the breathing test has dropped again, and your gap stage is now a 2, which does change the trajectory conversation. I noticed there's no advanced care planning documentation on file, so we should really get that sorted today. It's just a form, nothing to worry about, a form. Is this because it's getting worse? Well, the decline does meet, um, progression thresholds, but let's not get ahead of ourselves. Basically, we document your preferences, resuscitation, escalation, that kind of thing. So it's all on file. Some people involve family, that's an option. Does that sound OK? I suppose. I'd have to think. Great. Reception can print the paperwork and we'll pick it up at your next visit. You're doing really well, all things considered. Right Thank you, doctor. I'll tell you my impression was that this was, you know, it was a well meant discussion, but it was kind of a little bit rushed and a lot of jargon that was being used, um, and as we come back to trying to get a sense of proactive care, using a dashboard like we've sort of presented for you to, to highlight for us, understand we've got an at-risk person, because, you know, there, there's already a, a methodology that's been introduced to identify high-risk individuals. In this case, you, you know that she's at risk. Uh, as you progress in parallel, you're treating, you're monitoring, in her case, you saw her lung function going in that direction, and, and so you're supporting her with management of whatever therapeutic approach you've taken. At the same time, we wanna have you be able to understand in a person like Margaret. It's important to be able to be proactive in asking, what do you wanna do? What matters to you? What, what are your goals, uh, Margaret? Um, how do you wanna achieve those? Do you wanna do it pharmacologically, non-pharmacologically? Uh, do you wanna do it here or you wanna do it in a different location? And all of that has to be documented so that all of your colleagues that are involved in her care get a good sense of, of this approach to proactive management from the earliest stage of disease. To what we do as the stage progresses in appropriately establishing goals, plans, and maximizing satisfaction for all involved, particularly Margaret. Uh, and so this advanced care planning is not really the end of treatment. It's sort of like a safety rail that runs in parallel to, to maximize the outcomes that occur. So if, if I were gonna take away my impressions from, from this, uh, this presentation, the goal of what we're trying to achieve is that advanced care planning is longitudinal. It is, it's not dealing with whenever there's a crisis, uh, it is something that's based on the, the baseline assessment and then a very careful discussion with the patient of what the patient wants. Where she wants to do the care and, and what she wants as her ultimate goals, that, that same dashboard that guards adherence should aid you in management the conversation. This documentation of those discussions in your advanced care plan is gonna be useful for you, for Margaret, and for any other clinician that's involved in her care. And, and the idea of being supportive and being able to provide disease modifying therapy which we now have sort of runs in parallel. That, that's an, an advantage for you. It's an advantage most importantly for the patient. And so neither of those cancels the other. They're this joint uh care. I warned you this was coming again. So here's your poll. Again, the same question we asked earlier, how confident are you that you would recognize and act on early ILD management in a patient like Margaret? Same options from not at all confident all the way to completely confident. Uh, and so let's see how that's changed over the course of the last hour. All right. Here we come back to Margaret. Uh, so you, you know, gone through the diagnosis. Um, we, we've sort of asked Margaret, OK, listen, what do you think, uh, you would have wanted, uh, to have happened earlier? You, from the patient's point of view, it was important insight. What's your stance, Margaret? Let's see what she says. I don't think anyone did anything wrong, exactly, but my care team knew my lungs could be affected. I didn't. I wish that had been checked before I could feel anything, and I wish someone had clearly overseen the results and the conversation about what matters to me. I'd have been ready for that much earlier than anyone asked. All right. So, most importantly, when you participate in a program like this, to try to remember at least one thing that, that you're going to do differently. Uh, and so these are, these are potentially options, uh, for you to consider. It's most importantly for you and your practice setting. Uh, know what a risk profile looks like, um, so that you, you're establishing some thoughts regarding how you want to interact with Margaret before any symptoms occur, certainly before there's any crisis that's occurred. Uh, put that as a flag to yourself and act on that, uh, when you have an opportunity, um, give every flag an owner, so whenever you're documenting these components, in particularly if you have structured reports, which always simplify things, make sure that there's good documentation that you address these components of the advanced care planning. So that the multidisciplinary discussion, which is the gold standard for all of us in diagnosis and management, becomes part of the routine for all clinicians that are involved with managing Margaret during the course of her, of her journey, uh, and then, you know, treat tolerability as a treatment. You know, all of these drugs have challenging components, some less, some more. Be proactive in managing some of the particularly GI side effects with the patient. There is a, a, a broad, it's amazing the, the level of advance we've made in therapy and it's continuing to proceed. So, so Margaret's gonna have a lot of options, and so you're gonna have to really be able to document all of that, make sure that you've had those discussions with Margaret, they're recorded in your, in your action plan, and you close the loop with the patient. Because what, what's most important is what matters to her during the course of this longitudinal journey with you and aiding her with her care.